四因子前激素复合物缩剂与安德克萨尼特阿尔法相比,用于扭转创伤性脑损伤
Erin Sadek1, William Curtiss2, Jessica Andrews3
1Inpatient Pharmacy, Trinity Health Ann Arbor, Ann Arbor, Michigan, USA.
Emergency medicine journal : EMJ
|January 24, 2024
概括
四因子前激素复合物缩剂 (4F-PCC) 和安德克萨内特阿尔法在创伤性脑损伤 (TBI) 患者的死亡率和并发症方面显示出类似的结果. 需要进一步的研究来确定TBI患者服用抗凝剂的最佳逆转剂.
科学领域:
- 创伤外科 手术 创伤外科
- 神经临界护理是指神经临界护理.
- 药理学 药理学是指药理学的学科.
背景情况:
- 安德克萨内特阿尔法已被批准用于逆转直接口服抗凝剂,但成本和获取限制了其使用.
- 四因子前素复合缩物 (4F-PCC) 仍然是抗凝剂逆转的常见替代品.
- 在创伤性脑损伤 (TBI) 患者中,这些药物的比较有效性尚未得到充分证实.
研究的目的:
- 评估和比较与4F-PCC在患者与孤立创伤性脑损伤 (TBI) 的安德克萨内特阿尔法临床结果.
- 评估与每个逆转药物相关的死亡率,临终关怀率和严重的医院并发症.
主要方法:
- 35个创伤中心 (2014-2021) 的回顾性评估 (2014-2021),包括患者的缩略伤害量表 (AIS) 头部得分>2.
- 患者在入院后24小时内接受了安德克萨尼特α或4F-PCC.
- 多变量后勤回归根据TBI严重程度和并发症进行调整,以比较初级 (死亡率/临终关怀) 和二次 (严重并发症) 结果.
主要成果:
- 59名患者接受了安德克萨内特α,265名患者接受了4F-PCC;安德克萨内特α组的AIS头部得分较高 (47.5%对AIS5的26.1%).
- 调整后的分析显示,在安德克萨尼特阿尔法 (25.4%) 和4F-PCC (18.5%) 组 (OR 1.34;95% CI 0.67-2.71) 之间,死亡率/临终关怀没有显著差异.
- 严重TBI子组的结果和严重医院并发症的发生率在两组之间也是相似的.
结论:
- 关于4F-PCC与安德克萨内特α对单个TBI患者的死亡率/临终关怀或严重并发症的治疗效果,无法得出明确的结论.
- 该研究强调了4F-PCC的持续使用,尽管安德克萨内特阿尔法可用,可能是由于实际考虑.
- 需要进一步的研究,以阐明特定患者群体或临床情景的潜在差异.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
698
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
698
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.7K